SEC Form SC 13D/A filed by Shattuck Labs Inc. (Amendment)
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $15.00 | Overweight | Piper Sandler |
| 12/1/2025 | $6.00 | Neutral → Buy | H.C. Wainwright |
| 9/8/2025 | $4.00 | Outperform | Wedbush |
| 3/17/2025 | $4.00 | Outperform | Leerink Partners |
| 10/2/2024 | $8.00 → $2.00 | Buy → Neutral | Citigroup |
| 10/2/2024 | Buy → Hold | Needham | |
| 10/1/2024 | Buy → Neutral | H.C. Wainwright | |
| 6/17/2024 | Buy → Neutral | BTIG Research |
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026. Conference Details Conference: Piper Sandler Virtual Novel Targets in Immunology SymposiumFormat: Fireside chat Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andr
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the "Grant Date") to a newly-hired non-executive officer. The inducement awards consist of non-qualified stock options to purchase 206,000 shares of Shattuck's common stock with an exercise price of $3.23 per share. The stock options have a maximum term of 10 ye
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th Annual Healthcare ConferenceFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerPresentation Date: Dec 2, 2025Time: 10:10 AM ESTL
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
Piper Sandler initiated coverage of Shattuck Labs with a rating of Overweight and set a new price target of $15.00
H.C. Wainwright upgraded Shattuck Labs from Neutral to Buy and set a new price target of $6.00
Wedbush initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To
AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co
- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave
SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)
SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)